Transcode Therapeutics, INC

TransCode Therapeutics, Inc. announced the approval of several key proposals at its 2026 Annual Meeting of Stockholders, including stock issuances and director elections.

TransCode Therapeutics, Inc. has amended its Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, increasing the beneficial ownership limitation.

TransCode Therapeutics shared an update on its three-platform oncology pipeline, highlighting progress in its lead candidate TTX-MC138 and future development plans.

TransCode Therapeutics announced positive safety and disease stabilization data from its Phase 1a clinical trial of TTX-MC138 in metastatic cancer patients, advancing to Phase 2 development.

TransCode Therapeutics announced its 2026 Annual Meeting of Stockholders will be held on July 2, 2026, with a record date of May 28, 2026.

TransCode Therapeutics has received a deficiency letter from Nasdaq for failing to meet the minimum stockholders equity requirement and is developing a plan to regain compliance.

TransCode Therapeutics reports increased operating losses and a continued need for capital, with cash reserves projected to last only until year-end 2026.

TransCode Therapeutics reports a net loss of $17.8 million for Q1 2026 while securing new capital through a $14 million standby equity purchase agreement.

TransCode Therapeutics reports a significant Q3 with a strategic acquisition, a $25 million investment, and advancement in its lead clinical programs, despite increased net losses.

TransCode Therapeutics reported increased net loss for the first half of 2025 despite reduced operating expenses, while its lead cancer therapeutic candidate, TTX-MC138, showed positive safety data in its Phase I/II clinical trial.

TransCode Therapeutics reports a net loss of $12.1 million for Q1 2025 and faces potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.

TransCode Therapeutics' Q3 2024 report reveals ongoing losses, a cash runway into late 2024, and challenges with Nasdaq listing compliance.

TransCode Therapeutics files an amendment to its 2025 Annual Report to include required Part III disclosures.

TransCode Therapeutics, Inc. has entered into a significant equity issuance and registration rights agreement with Unleash Immuno Oncolytics, Inc., alongside a standby equity purchase agreement with YA II PN, LTD, bolstering its financial and strategic position.

TransCode Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

TransCode Therapeutics faces financial hurdles but progresses with clinical trials and preclinical programs in RNA-based cancer therapies.

TransCode Therapeutics' 10-K filing highlights the company's progress in developing its RNA oncology platform, including its lead candidate TTX-MC138, and its financial position.

Director Magda Marquet reports the acquisition of stock options in Transcode Therapeutics.

Director Erik Manting acquired 70,000 stock options in Transcode Therapeutics, Inc. on June 14, 2024.

Thomas A. Fitzgerald, Interim CEO and CFO of Transcode Therapeutics, acquired 650,000 stock options on June 14, 2024.

Director Calais Philippe reports the acquisition of stock options in Transcode Therapeutics, Inc.

TransCode Therapeutics, Inc. completes the acquisition of immuno-oncology firm ABCJ, LLC, adding a phase 3-ready melanoma vaccine to its pipeline, alongside a $25 million investment.

TransCode Therapeutics amended its Series A and B Preferred Stock terms, clarifying conversion limits and removing delisting-triggered conversion rights, pending shareholder approval for a larger transaction.

TransCode Therapeutics, Inc. filed an amendment to its Form 8-K/A, clarifying the effective date and rights agent for its Contingent Value Rights Agreement, which outlines future payments to shareholders from asset monetization.

TransCode Therapeutics, Inc. filed an amendment to correct the price per share for its Series B Preferred Stock, detailing the acquisition of ABCJ, LLC and a concurrent $25 million private placement investment from DEFJ, LLC.

TransCode Therapeutics announced the acquisition of Polynoma LLC and a concurrent $25 million strategic financing from a CK Life Sciences subsidiary, expanding its oncology pipeline with a Phase 3-ready asset.

TransCode Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders will be held virtually on August 29, 2025, to vote on the election of four directors, an amendment to increase shares available under its 2021 Stock Option and Incentive Plan by 166,724 shares, and the ratification of its independent registered public accounting firm.

TransCode Therapeutics is registering the resale of common stock and warrants issued in a recent private placement, as the company continues to develop its oncology-focused platform.

TransCode Therapeutics is offering shares and warrants to fund its oncology platform, including its lead candidate TTX-MC138, while facing Nasdaq compliance challenges.

TransCode Therapeutics implements a 1-for-40 reverse stock split and launches a public offering of common stock and warrants to advance its oncology-focused RNA therapeutic platform.

TransCode Therapeutics is seeking to raise up to $7.5 million through a public offering of common stock and warrants to advance its oncology-focused RNA therapeutic programs.

DEFJ, LLC and CK Life Sciences Int'l. (Holdings) Inc. have converted substantial preferred stock into common shares, increasing their beneficial ownership.

DEFJ, LLC and CK Life Sciences Int'l. (Holdings) Inc. report a conversion of Series B Preferred Stock into common stock, bringing their beneficial ownership to 9.9% of TransCode Therapeutics.

DEFJ LLC has submitted a conversion notice for Series B Preferred Stock in TransCode Therapeutics, Inc., contingent on stockholder approval of key proposals.

TransCode Therapeutics, Inc. has amended its Contingent Value Rights Agreement and the terms of its Series A and B Preferred Stock, impacting conversion limitations and delisting provisions.

TransCode Therapeutics, Inc. completed the acquisition of ABCJ, LLC from DEFJ, LLC and secured a $25 million private placement, issuing common and preferred stock, and contingent value rights.

Investor Thomas J. Tracy has disclosed a 5.0% beneficial ownership stake in Transcode Therapeutics, Inc., signaling an intent to engage with management and the Board on strategies to enhance shareholder value, including commercialization and fundraising approaches.

Unleash Immuno Oncolytics, Inc. has filed a Schedule 13G, reporting beneficial ownership of 300,000 shares, representing 9.94% of the outstanding common stock of TransCode Therapeutics, Inc.

Elena Rosa Braci has filed a Schedule 13G, reporting beneficial ownership of 186,236 shares, representing 6.17% of TransCode Therapeutics, Inc.'s common stock.

Daniel Eduardo Katzman has reported beneficial ownership of 155,611 shares, representing 5.16% of the outstanding common stock of TransCode Therapeutics, Inc.

Yorkville Advisors and affiliates have reported a 9.9% beneficial ownership stake in TransCode Therapeutics following a convertible note purchase.

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly disclosed a passive 4.9% beneficial ownership in Transcode Therapeutics, Inc. common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a passive beneficial ownership of 82 shares, representing 0.0% of Transcode Therapeutics Inc. common stock.